Latest Earnings

Stock Analysis

Stock Movers

Deals

Gainers And Losers

Equities

IPOs

Artificial Intelligence

Technology

Web Stories

Benzinga Inspire

Dmitry Reykhart is a successful business professional with over 30 years of experience in the pharmaceutical industry. He holds a Ph.D. and a Doctor of Science degree in pharmacology and clinical pharmacology, giving him a deep understanding of the field. In addition to his expertise in the pharmaceutical industry, Dmitry has also spent 15 years working in financial services. He is an inventor of an innovative investment strategy that utilizes structured products and financial engineering in the pharmaceutical and biotech sectors. He is the founder of the Ruthenium Global Pharma Fund, based in Luxembourg. Throughout his career, Dmitry has been dedicated to finding new and innovative ways to drive growth and success in the pharmaceutical industry, and his achievements in both the pharmaceutical and financial sectors speak to his expertise and leadership.

Articles written by Dmitry Reichart

Biotech

General

RHHBY


	The discovery of immune checkpoint proteins was a breakthrough in cancer immunotherapy.
	Today, Merck, Roche, and Bristol Myers are leading the immuno-oncology race, with Merck&#39;s Keytruda dominating. Bristol Myers&#39;s Opdivo is one step behind, while Roche is still looking for its niches after several failures. 


Victories And failures Of Roche, Bristol Myers, and Merck And Why It&#39;s Worth Investing In Immunotherapy Now

Markets


	The pharmaceutical market is least affected by negative events in the world economy
	Specialized strategies which take into account peculiarities of different markets are efficient
	The actual return in pharma has already reached 24.85% and a YTD return is currently 7.35%. 




Investment In The Pharmaceutical Market During The Recession: New Reality Of Market

Dmitry Reykhart

About